Tarsius Pharma has been awarded a 2.4 million euro Horizon 2020 Grant from the European Commission to support a clinical trial of TRS01, the company’s bioinspired technology, according to a press release.
TRS01 is a new molecule developed to approach autoimmune and inflammatory ocular diseases by “re-engineering” the immune system, the release said.
“We are delighted to be awarded the Horizon 2020 Grant, which validates the need for a viable solution where other approaches have been unsuccessful in treating this patient population,” Daphne Haim-Langford, PhD,
Uncategorized